SOST
ENSG00000167941
Target class
Unclassified protein
Chromosome
17
Approved drugs
1
Clinical candidates (approved and in development)
5
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 5
- Chemical probe available
- No
- Target name
- SOST
- Gene name
- Sclerostin
- Gene symbol
- SOST
- Protein name
- Sclerostin
- VBCH
- DAND6
- Gene biotype
- Protein coding
- Gene family
- DAN family
- Target class
- Unclassified protein
- Target type
- Human gene
- Tissues expressed in
- 5
- Highest tissue expression
- 71.74
- Tissue specificity (Gini)
- 0.954
- Tissue specificity (tau)
- 0.988
- KEGG gene identifiers
- hsa:50964
- Protein interaction confidence
- 0.819
- Protein interaction partners
- 32
- R-HSA-201681
- R-HSA-3772470
- End position
- 43758791
- Start position
- 43753738
- Chromosome
- 17
- Strand
- Reverse
- Secreted, extracellular space, extracellular matrix .
Publication evidence
- PubMed 20551380
- Tissue specificity (tau)
- 0.988191
- Expression inequality (Gini)
- 0.953891
Expression in transcripts per million
- Artery - Aorta
- 71.74
- Artery - Tibial
- 29.99
- Kidney - Cortex
- 7.06
- Artery - Coronary
- 4.4
- Kidney - Medulla
- 1.82
Expression in transcripts per million
- Artery - Aorta71.74
- Artery - Tibial29.99
- Kidney - Cortex7.06
- Artery - Coronary4.4
- Kidney - Medulla1.82
- Heart - Atrial Appendage0.41
- Testis0.12
- Lung0.1
- Skin - Sun Exposed (Lower leg)0.09
- Brain - Frontal Cortex (BA9)0.08
- Nerve - Tibial0.07
- Brain - Cortex0.07
- Vagina0.05
- Thyroid0.04
- Skin - Not Sun Exposed (Suprapubic)0.04
- Spleen0.04
- Prostate0.04
- Adipose - Subcutaneous0.03
- Pituitary0.03
- Brain - Cerebellum0.03
- Brain - Hypothalamus0.03
- Adipose - Visceral (Omentum)0.02
- Fallopian Tube0.02
- Uterus0.02
- Adrenal Gland0.02
And 29 more, listed on the interactive page.
- GO:0009612
- GO:0030514
- GO:0031333
- GO:0045893
- GO:0071374
- GO:0090090
Cellular components
- GO:0005576
- GO:0005515
- GO:0030246
- GO:0140297
- GO:0140678
Related records
Trials (61)
- A First-in-human Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women
- A First-in-human Study Evaluating Romosozumab (AMG 785) in Healthy Men and Postmenopausal Women
- A Multiple Dose Study of LY2541546 in Healthy Postmenopausal Women
- A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Romosozumab (AMG 785)
- A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis
- A Safety and Efficacy Study to Evaluate Romosozumab (AMG 785) in South Korean Women With Osteoporosis
- A Single-dose Study Evaluating Romosozumab (AMG 785) in Healthy Postmenopausal Japanese and Non-Japanese Women
- A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804
- A Study of 2 Different Formulations of Blosozumab (LY2541546) in Post Menopausal Women
- A Study of Blosozumab (LY2541546) in Postmenopausal Female Participants
- A Study of LY2541546 in Healthy Postmenopausal Women
- A Study of LY2541546 in Women With Low Bone Mineral Density
- A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture.
- A Study of Romosozumab in People With Breast Cancer and Osteoporosis
- A Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis
- A Study to Compare the Safety and Efficacy of Romosozumab (AMG 785) Versus Placebo in Men With Osteoporosis
- A Study to Evaluate the Effect of Romosozumab (AMG 785) on Bone Quality of the Forearm in Postmenopausal Women With Low Bone Mass
- A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis
- An Ascending Multiple Dose Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women With Low Bone Mineral Density
- An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta
Drugs (5)
- AMG-167 Sclerostin inhibitor
- Anti-sclerostin Sclerostin inhibitor
- Blosozumab Sclerostin inhibitor
- Romosozumab Sclerostin inhibitor
- Setrusumab Sclerostin inhibitor